vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
Stock Information for vTv Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.